瑞他霉素盐酸盐
中文名称:
瑞他霉素盐酸盐
中文同义词:
瑞他霉素盐酸盐;HSP90ATPASE活性抑制剂
英文名称:
Unii-928Q33Q049
英文同义词:
IPI-504;IPI504;IPI 504;17-Allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride;Ipi 504;Ipi-504;Unii-928Q33Q049;18,21-Didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propen-1-ylamino)geldanamycin hydrochloride;Retaspimycin hydrochloride;IPI-504 (RetaspiMycin hydrochloride)
CAS号:
857402-63-2
分子式:
C31H47N3O8.ClH
分子量:
626.186
EINECS号:
200-258-5
相关类别:
细胞生物学试剂
Mol文件:
857402-63-2.mol
生物活性
Retaspimycin Hydrochloride是有效的 Hsp90 抑制剂，EC50 为119 nM。
靶点
HSP90
119 nM (EC 50 )
GRP94
119 nM (EC 50 )
HSP90
119 nM (EC 50 )
GRP94
119 nM (EC 50 )
体外研究
Retaspimycin (IPI-504) is a novel and highly soluble analog of 17AAG, an inhibitor of Hsp90. Retaspimycin can abrogate both the unfolded protein response element (UPRE) and ERSE-driven luciferase activity in non-treated U266 and MM.1s cells as well as in Tunicamycin (Tm)-treated cells. The IC 50 s for the inhibition of reporter gene activity by Retaspimycin are 196±56 nM in U266 and 472±177 nM in MM.1s for UPRE-luc activity and 213±140 nM for the ERSE-driven activity in MM.1s cells. Retaspimycin treatment leads to a dose-dependent decrease of p50ATF6 with EC 50 of 237 nM, consistent with the reporter-gene assay. The level of sXBP1 is decreased in the presence of Retaspimycin with an apparent EC 50 between 300 nM and 1 μM. Incubation of Retaspimycin (IPI-504) potently suppresses both Akt and MAPKs phosphorylation in both sensitive and Trastuzumab-resistant cells. Total levels of Akt decreased in all 4 cell lines (BT474, SKBR-3, HCC1569, and HCC1569) in a dose-dependent manner. However, levels of total MAPKs are not significantly altered with Retaspimycin treatment.
体内研究
Retaspimycin (IPI-504) and Trastuzumab independently induce tumor regression of Trastuzumab-sensitive BT474 cell-derived xenografts. Xenografts derived from BT474R cells continue to grow in the presence of Trastuzumab but are still sensitive to Retaspimycin. When used in combination, Retaspimycin and Trastuzumab add only marginal benefits to Retaspimycin monotherapy. Retaspimycin (100 mg/kg) as a single agent is more efficacious than Trastuzumab in inhibiting tumor growth in HCC1569 xenografts. The combination is not significantly superior to Retaspimycin used as a single agent.
